NOD.CB17-PrkdcscidIl2rgtm1BcgenB2mtm1(B2M/HLA-A2.1)BcgenFcgrttm1(B2m/Fcgrt)Bcgen/Bcgen • 112449
| Product name | B-NDG hB2M/HLA-A2.1 mice plus |
|---|---|
| Catalog number | 112449 |
| Strain name | NOD.CB17-PrkdcscidIl2rgtm1BcgenB2mtm1(B2M/HLA-A2.1)BcgenFcgrttm1(B2m/Fcgrt)Bcgen/Bcgen |
| Strain background | B-NDG |
| NCBI gene ID | 2217,3105,3561,5591,567 (Human) |
| Aliases | CD132; CIDX; IL-2RG; IMD4; P64; SCIDX; SCIDX1; DNA-PKC; DNA-PKcs; DNAPK; DNAPKc; DNPK1; HYRC; HYRC1; IMD26; XRCC7; p350; FCRN; alpha-chain; HLAA; IMD43; IMD43; HLAA; FCRN; alpha-chain; DNA-PKC; p350; CD132 |
| Application | To verify the efficacy of HLA-A2.1 restricted vaccines and antibody-based therapies；Promote the development of human CD8+ T cells |
Gene targeting strategy for B-NDG HLA-2.1 mice. The B2m gene (Exon1 to Exon3) of mouse was replaced by the sequence encompassing the human B2M CDS and HLA-A2.1 gene in B-NDG HLA-2.1 mice. The mouse B2m gene was knocked out while a fused gene composed of mouse B2m and Fcgrt gene was inserted after the signal peptide sequence of mouse Fcgrt gene in B-NDG B2m KO mice plus. The B-NDG HLA-2.1 mice were mated with B-NDG B2m KO mice plus to obtain a new mouse strain named B-NDG hB2M/HLA-A2.1 mice plus.
Pharmacokinetic characteristic of B-NDG hB2M/HLA-A2.1 mice plus has no difference compared with B-NDG mice. B-NDG mice, B-NDG HLA-A2.1 mice, B-NDG hB2M/HLA-A2.1 mice plus were treated with YH001 (anti-human CTLA4 antibody) (n=4). Blood samples were collected at different time point for the PK assay. The results showed that the PK results of B-NDG hB2M/HLA-A2.1 mice plus group was similar to that in B-NDG mice, and the drug concentration of B-NDG HLA-A2.1 mice group could not be measured at the time point 4 days later. Results indicated that when compared with B-NDG HLA-A2.1 mice, the B-NDG hB2M/HLA-A2.1 mice plus can significantly extend the half-life of antibody drugs in mice.
